JP2014237658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014237658A5 JP2014237658A5 JP2014141894A JP2014141894A JP2014237658A5 JP 2014237658 A5 JP2014237658 A5 JP 2014237658A5 JP 2014141894 A JP2014141894 A JP 2014141894A JP 2014141894 A JP2014141894 A JP 2014141894A JP 2014237658 A5 JP2014237658 A5 JP 2014237658A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- granules
- disintegrant
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 79
- 239000000203 mixture Substances 0.000 claims description 43
- 239000008187 granular material Substances 0.000 claims description 33
- 239000007884 disintegrant Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- 238000009472 formulation Methods 0.000 claims description 24
- 239000006186 oral dosage form Substances 0.000 claims description 20
- 239000011230 binding agent Substances 0.000 claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 17
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical group CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 claims description 12
- 229960003233 eslicarbazepine acetate Drugs 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 4
- 238000007906 compression Methods 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 7
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 6
- 229960001681 croscarmellose sodium Drugs 0.000 claims 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 6
- 235000003599 food sweetener Nutrition 0.000 claims 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 6
- 229940069328 povidone Drugs 0.000 claims 6
- 239000003765 sweetening agent Substances 0.000 claims 6
- 239000000796 flavoring agent Substances 0.000 claims 5
- 235000013355 food flavoring agent Nutrition 0.000 claims 5
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000000945 filler Substances 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- -1 glidant Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000008213 purified water Substances 0.000 claims 2
- 238000005550 wet granulation Methods 0.000 claims 2
- 229920002261 Corn starch Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 229960004667 ethyl cellulose Drugs 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 229960002900 methylcellulose Drugs 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 101000748137 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 31 Proteins 0.000 description 1
- 101000759988 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 48 Proteins 0.000 description 1
- 102100025023 Ubiquitin carboxyl-terminal hydrolase 48 Human genes 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98279007P | 2007-10-26 | 2007-10-26 | |
| US60/982,790 | 2007-10-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530951A Division JP2011500797A (ja) | 2007-10-26 | 2008-10-24 | 酢酸リカルバゼピンを含む経口剤形 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016147183A Division JP2017014233A (ja) | 2007-10-26 | 2016-07-27 | 酢酸リカルバゼピンを含む経口剤形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014237658A JP2014237658A (ja) | 2014-12-18 |
| JP2014237658A5 true JP2014237658A5 (cg-RX-API-DMAC7.html) | 2016-02-12 |
| JP6043758B2 JP6043758B2 (ja) | 2016-12-14 |
Family
ID=40254311
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530951A Pending JP2011500797A (ja) | 2007-10-26 | 2008-10-24 | 酢酸リカルバゼピンを含む経口剤形 |
| JP2014141894A Expired - Fee Related JP6043758B2 (ja) | 2007-10-26 | 2014-07-10 | 酢酸リカルバゼピンを含む経口剤形 |
| JP2016147183A Pending JP2017014233A (ja) | 2007-10-26 | 2016-07-27 | 酢酸リカルバゼピンを含む経口剤形 |
| JP2018120334A Pending JP2018172407A (ja) | 2007-10-26 | 2018-06-26 | 酢酸リカルバゼピンを含む経口剤形 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530951A Pending JP2011500797A (ja) | 2007-10-26 | 2008-10-24 | 酢酸リカルバゼピンを含む経口剤形 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016147183A Pending JP2017014233A (ja) | 2007-10-26 | 2016-07-27 | 酢酸リカルバゼピンを含む経口剤形 |
| JP2018120334A Pending JP2018172407A (ja) | 2007-10-26 | 2018-06-26 | 酢酸リカルバゼピンを含む経口剤形 |
Country Status (24)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| US8372431B2 (en) | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
| US9387191B2 (en) | 2009-07-21 | 2016-07-12 | Keryx Biopharmaceuticals, Inc. | Ferric citrate dosage forms |
| UA106384C2 (ru) | 2009-07-27 | 2014-08-26 | БИАЛ-ПОРТЕЛА энд КА., С.А. | ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ 5H-ДИБЕНЗ/б,ф/АЗЕПИН-5-КАРБОКСАМИДА ДЛЯ ЛЕЧЕНИЯ ФИБРОМИАЛГИИ |
| CA2777937C (en) | 2009-10-26 | 2017-08-29 | Merck Sharp & Dohme Corp. | Solid pharmaceutical compositions containing an integrase inhibitor |
| US20120121703A1 (en) * | 2010-07-20 | 2012-05-17 | Japan Tobacco Inc. | Tablet containing ferric citrate |
| TR201008460A1 (tr) | 2010-10-15 | 2012-05-21 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Eslikarbazepinin saşe formülasyonları. |
| JP6133786B2 (ja) * | 2010-12-31 | 2017-05-24 | ビアル−ポルテラ エ コンパニア，ソシエダッド アノニマ | エスリカルバゼピンアセテート含有顆粒 |
| WO2013032351A1 (en) | 2011-08-26 | 2013-03-07 | BIAL - PORTELA & Cª, S.A. | Treatments involving eslicarbazepine acetate or eslicarbazepine |
| EP3103444A1 (en) | 2015-06-09 | 2016-12-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical compositions of lacosamide and eslicarbazepine |
| US10918604B2 (en) * | 2015-12-18 | 2021-02-16 | Jubilant Generics Limited | Solid oral dosage forms of eslicarbazepine |
| KR102280457B1 (ko) * | 2016-06-29 | 2021-07-23 | 엘티디 "발렌타-인텔렉트" | 메만틴 및 멜라토닌의 배합물을 함유하는 약제학적 조성물 |
| CN106913550B (zh) * | 2017-03-10 | 2019-12-17 | 扬子江药业集团北京海燕药业有限公司 | 一种醋酸艾司利卡西平片的制备方法 |
| US11318145B2 (en) | 2018-09-25 | 2022-05-03 | Jubilant Generics Limited | Eslicarbazepine suspension |
| WO2019058354A1 (en) * | 2017-09-25 | 2019-03-28 | Jubilant Generics Limited | SUSPENSION OF ESLICARBAZÉPINE |
| EA037195B1 (ru) * | 2018-03-28 | 2021-02-18 | Акционерное Общество "Химфарм" | Биологически активная добавка для улучшения функционального состояния дыхательной системы и восстановления иммунной системы (варианты) |
| WO2020054647A1 (ja) | 2018-09-14 | 2020-03-19 | 学校法人慶應義塾 | アストロサイトの製造方法 |
| HUP1900153A1 (hu) | 2019-05-14 | 2020-11-30 | Meditop Gyogyszeripari Kft | Eszlikarbazepin-acetát tartalmú granulátum, ennek elõállítása, ezt tartalmazó egyéb gyógyszerkészítmények, és ezek alkalmazása |
| EP4146172A1 (en) * | 2020-05-05 | 2023-03-15 | NeuroBo Pharmaceuticals, Inc. | Niclosamide formulations and methods of use |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| ZA953078B (en) | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
| PT101732B (pt) | 1995-06-30 | 1997-12-31 | Portela & Ca Sa | Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso |
| US6296873B1 (en) * | 1997-01-23 | 2001-10-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Zero-order sustained release delivery system for carbamazephine derivatives |
| CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| GB9721497D0 (en) | 1997-10-09 | 1997-12-10 | Ciba Geigy Ag | Organic compounds |
| TR200001856T2 (tr) * | 1997-12-19 | 2000-11-21 | Smithkline Beecham Corporation | Isırınca ağızda dağılan tabletlerin yapım prosesi |
| SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| IN190699B (cg-RX-API-DMAC7.html) * | 2001-02-02 | 2003-08-16 | Sun Pharmaceutical Ind Ltd | |
| GB0111566D0 (en) | 2001-05-11 | 2001-07-04 | Portela & Ca Sa | Method for preparation of (s)-(+)-and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azephine-5-carboxamide |
| GB0112812D0 (en) | 2001-05-25 | 2001-07-18 | Portela & Ca Sa | Mthd for preparation of 10, 11-dihydro-10-hydroxy-5H-dibenz/B,F/azepine-5-c arboxamide and 10,11-dihydro-10-oxo-5H-dibenz/B,F/azepine-5-carb oxamide therefrom |
| WO2003075830A2 (en) * | 2002-03-14 | 2003-09-18 | Sun Pharmaceutical Industries Limited | Oral controlled drug delivery system containing carbamazepine |
| DE10224170A1 (de) | 2002-05-31 | 2003-12-11 | Desitin Arzneimittel Gmbh | Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung |
| AU2003240654A1 (en) | 2002-05-31 | 2003-12-19 | Desitin Arzneimittel Gmbh | Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release |
| DE10230027A1 (de) | 2002-07-04 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen auf der Basis von Natriumkanalblockern und Magnesiumsalzen |
| GB0221956D0 (en) | 2002-09-20 | 2002-10-30 | Novartis Ag | Organic compounds |
| AU2003280393A1 (en) | 2002-10-17 | 2004-05-04 | Novartis Ag | Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |
| US20040087642A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
| GB2401605A (en) | 2003-05-12 | 2004-11-17 | Portela & Ca Sa | Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof |
| EP1750717B1 (en) * | 2004-02-11 | 2017-07-19 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| CN1934145B (zh) | 2004-03-17 | 2011-01-19 | 帝斯曼知识产权资产管理有限公司 | 包括脒配体的聚合催化剂 |
| AR048318A1 (es) * | 2004-03-22 | 2006-04-19 | Novartis Ag | Formulaciones de matriz orales que comprenden licarbazepina |
| AR048672A1 (es) | 2004-03-22 | 2006-05-17 | Novartis Ag | Tabletas de desintegracion que comprenden licarbazepina |
| GB2416167A (en) | 2004-07-13 | 2006-01-18 | Portela & Ca Sa | Chiral inversion and esterification of (S)- and (R)-10-hydroxy-dibenzazepine carboxamides |
| EP2098223A1 (en) | 2004-11-10 | 2009-09-09 | Teva Pharmaceutical Industries Ltd. | Compressed solid dosage form |
| GB0425320D0 (en) | 2004-11-17 | 2004-12-22 | Johnson Matthey Plc | Diamines |
| GB2422149A (en) | 2005-01-14 | 2006-07-19 | Portela & Ca Sa | Process for the preparation of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide |
| BRPI0520258A2 (pt) | 2005-05-06 | 2009-09-15 | Portela & Ca Sa | uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina |
| JP2008540405A (ja) | 2005-05-06 | 2008-11-20 | ポルテラ・アンド・シーエー・エスエー | 酢酸エスリカルバゼピン及び使用方法 |
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| US8059672B2 (en) | 2005-05-18 | 2011-11-15 | Sprint Communications Company L.P. | Internet communications between wireless base stations and service nodes |
| US20070071819A1 (en) * | 2005-05-30 | 2007-03-29 | Kesarwani Amit K | Multiple unit modified release compositions of carbamazepine and process for their preparation |
| US20090143360A1 (en) | 2005-07-08 | 2009-06-04 | Muhammed Safadi | Oxcarbazepine Formulation |
| GB0515690D0 (en) | 2005-07-29 | 2005-09-07 | Portela & Ca Sa | Asymmetric catalytic reduction |
| WO2007029093A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Pharmaceutical dosage forms of oxcarbazepine |
| JP2008540346A (ja) | 2006-01-31 | 2008-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | オキシカルバゼピンの医薬製剤及びその調製方法 |
| US20070178164A1 (en) | 2006-01-31 | 2007-08-02 | Sigal Blau | Pharmaceutical formulations of oxcarbazepine and methods for its preparation |
| GB0603008D0 (en) | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| GB2437078A (en) | 2006-04-11 | 2007-10-17 | Portela & Ca Sa | 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives |
| EP2077822B1 (en) | 2006-09-27 | 2018-04-25 | Medley S.A. Indústria Farmacêutica | Oxcarbazepine-containing oral formulation and a process to obtain the same |
| US20080138403A1 (en) | 2006-12-08 | 2008-06-12 | Sun Pharmaceutical Industries Ltd. | Pharmaceutical dosage forms of oxcarbazepine |
| US8372431B2 (en) | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
| US10918604B2 (en) | 2015-12-18 | 2021-02-16 | Jubilant Generics Limited | Solid oral dosage forms of eslicarbazepine |
-
2008
- 2008-10-23 US US12/257,240 patent/US8372431B2/en active Active
- 2008-10-24 RS RS20160895A patent/RS55376B1/sr unknown
- 2008-10-24 EP EP08842368.6A patent/EP2214636B1/en active Active
- 2008-10-24 CN CN200880112983A patent/CN101848698A/zh active Pending
- 2008-10-24 PT PT88423686T patent/PT2214636T/pt unknown
- 2008-10-24 JP JP2010530951A patent/JP2011500797A/ja active Pending
- 2008-10-24 KR KR1020167036806A patent/KR20170004034A/ko not_active Ceased
- 2008-10-24 PT PT161806872T patent/PT3202392T/pt unknown
- 2008-10-24 EP EP16180687.2A patent/EP3202392B1/en active Active
- 2008-10-24 KR KR1020187037643A patent/KR102116087B1/ko active Active
- 2008-10-24 HU HUE08842368A patent/HUE030788T2/en unknown
- 2008-10-24 MX MX2010004323A patent/MX2010004323A/es active IP Right Grant
- 2008-10-24 CA CA2703313A patent/CA2703313C/en active Active
- 2008-10-24 PL PL08842368T patent/PL2214636T3/pl unknown
- 2008-10-24 DK DK08842368.6T patent/DK2214636T3/en active
- 2008-10-24 BR BRPI0818680-4A patent/BRPI0818680B1/pt not_active IP Right Cessation
- 2008-10-24 AU AU2008317584A patent/AU2008317584B2/en active Active
- 2008-10-24 LT LTEP08842368.6T patent/LT2214636T/lt unknown
- 2008-10-24 ES ES16180687T patent/ES2898202T3/es active Active
- 2008-10-24 SI SI200831687A patent/SI2214636T1/sl unknown
- 2008-10-24 AR ARP080104652A patent/AR069031A1/es unknown
- 2008-10-24 ES ES08842368.6T patent/ES2607002T3/es active Active
- 2008-10-24 KR KR1020107011233A patent/KR20100093057A/ko not_active Ceased
- 2008-10-24 WO PCT/PT2008/000043 patent/WO2009054743A1/en not_active Ceased
- 2008-10-24 RU RU2010121135/15A patent/RU2546521C2/ru active
- 2008-10-24 UA UAA201006417A patent/UA110012C2/ru unknown
- 2008-10-24 HR HRP20161329TT patent/HRP20161329T1/hr unknown
-
2010
- 2010-04-18 IL IL205160A patent/IL205160A0/en unknown
-
2013
- 2013-01-30 US US13/754,439 patent/US20130150348A1/en not_active Abandoned
- 2013-12-17 US US14/108,615 patent/US9566244B2/en active Active
-
2014
- 2014-07-10 JP JP2014141894A patent/JP6043758B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-27 JP JP2016147183A patent/JP2017014233A/ja active Pending
- 2016-12-14 CY CY20161101294T patent/CY1118350T1/el unknown
-
2017
- 2017-01-04 US US15/397,945 patent/US10912781B2/en active Active
-
2018
- 2018-06-26 JP JP2018120334A patent/JP2018172407A/ja active Pending
-
2021
- 2021-01-29 US US17/248,581 patent/US20210322436A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014237658A5 (cg-RX-API-DMAC7.html) | ||
| JP2011500797A5 (cg-RX-API-DMAC7.html) | ||
| TWI750143B (zh) | 含有2-{4-[n-(5,6-二苯基吡-2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物 | |
| JP2015511635A5 (cg-RX-API-DMAC7.html) | ||
| RU2010121135A (ru) | Лекарственные формы для перорального применения, содержащие ацетат ликарбазепина | |
| WO2011160541A1 (zh) | 托伐普坦固体分散体及其制备方法 | |
| JP6496084B2 (ja) | 口腔内崩壊錠 | |
| JP6804585B2 (ja) | 医薬剤形 | |
| JP6630229B2 (ja) | レベチラセタム含有医薬組成物及びその製造方法 | |
| JP6716464B2 (ja) | 酢酸亜鉛水和物錠及びその製造方法 | |
| CN101659643A (zh) | 一种氢氯噻嗪的晶形及其用途 | |
| NO329206B1 (no) | Granulering og preparat med hoyt legemiddelinnhold, fremgangsmate for fremstilling derav og farmasoytisk preparat. | |
| JP2006328000A (ja) | 経口投与用製剤 | |
| JP6326114B2 (ja) | レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤 | |
| CN108324697B (zh) | 一种含枸橼酸莫沙必利的胶囊剂及其制备方法 | |
| JP2013216701A (ja) | 経口投与用製剤 | |
| JP7407364B2 (ja) | ラメルテオン含有固形製剤 | |
| JP6883401B2 (ja) | アジルサルタン含有錠剤及び錠剤におけるアジルサルタンの安定化方法 | |
| JP2017002022A (ja) | ボリコナゾール含有製剤 | |
| WO2015069203A1 (en) | Capsule comprising rupatadine fumarate and montelukast sodium | |
| JP6002869B1 (ja) | ジエノゲスト含有錠剤 | |
| JP5910311B2 (ja) | 医薬錠剤およびその製造方法 | |
| JP6176246B2 (ja) | 固形医薬錠剤およびその製造方法 | |
| JP2019089758A (ja) | セレコキシブ含有錠剤における溶出性の改善方法 | |
| WO2010062996A2 (en) | Ribavirin composition |